NYSEAMERICAN:BPMXBiopharmx Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biopharmx.

Biopharmx Corp (NYSEAMERICAN:BPMX) announced its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.64) by $0.96. View Biopharmx's earnings history.

Biopharmx shares reverse split before market open on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 8 shares after the split.

1 equities research analysts have issued 1 year price objectives for Biopharmx's shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Biopharmx's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 453.0% from the stock's current price. View analysts' price targets for Biopharmx.

Media headlines about BPMX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biopharmx earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about Biopharmx.

Some companies that are related to Biopharmx include Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Ergomed (ERGO), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Exicure (XCUR), OncoCyte (OCX), Theratechnologies (TH), Exicure (XCUR), Enochian Biosciences (ENOB), Novacyt (NCYT), Rafael (RFL) and Pfenex (PFNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix Biotherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BPMX stock can currently be purchased for approximately $2.17.

Biopharmx has a market capitalization of $39.66 million. Biopharmx employs 17 workers across the globe.

The official website for Biopharmx is www.biopharmx.com.

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.